Building a Product Line That Does Not Depend on a Cannabinoid
The strategic question is not which cannabinoid replaces the last one. It is which of your customers were buying the effect.
True to Plant EditorialAugust 5, 2026
Regulatory and compliance briefings for terpene buyers, formulators and QA teams.
The strategic question is not which cannabinoid replaces the last one. It is which of your customers were buying the effect.
True to Plant EditorialAugust 5, 2026
A can is one container, which puts drinks at the sharp end of the new cap. The reformulation is harder than the strategy decks suggest.
True to Plant EditorialAugust 4, 2026
Your existing certificates answer the old question correctly. That is the problem.
True to Plant EditorialAugust 3, 2026
A working brief for the people who have to action this. What the statute says, which SKUs it reaches, and the order to do things in.
True to Plant EditorialAugust 3, 2026
The pivot everyone is recommending raises your specification rather than lowering it. Here is what it actually requires.
True to Plant EditorialAugust 1, 2026
Most supplier conversations this quarter will be reassuring and verbal. These are the questions that need a document behind them.
True to Plant EditorialJuly 29, 2026
Everyone is modelling the milligram cap. There is a separate clause that turns on channel rather than content, and it catches a real business model.
True to Plant EditorialJuly 22, 2026
The cap is not what most summaries say it is. It is per container, and it is combined. Both details change what you can build.
True to Plant EditorialJuly 17, 2026
Rescheduling changed less than the headlines suggested, and what it did change is split by licence type. That split matters for sourcing.
True to Plant EditorialJuly 13, 2026
The question comes up in every sourcing call this year. The answer is in the scope of the guidance, and the scope is narrower than the rumour.
True to Plant EditorialJuly 6, 2026